Table 1 Baseline characteristics of patients who received once-weekly teriparatide injections for 18 months

Sex (n)

Female: 7, male: 2

Age (year)

57.4 ± 11.1

Disease (n)

SLE 6, RA 2, AOSD 1

PSL dose at baseline (mg/day)

10 ± 6.6

Fracture events within 18 months before TPTD treatment (n)

8 events of 7 patients

Lumbar spine YAM (%)

73.1 ± 11.9

Total hip YAM (%)

72 ± 10.0

Lumbar spine BMD

0.74 ± 0.11

Total hip BMD

0.62 ± 0.11

Ca (mg/dl)

9.1 ± 0.5

BAP (µg/L)

Reference value; male 3.7–20.9, Premenopausal female 2.9–14.5, Postmenopausal female 3.8–22.6

10.8 ± 4.6

Serum NTx (nmol BCE/L)

Reference value; Male 9.5–17.7, Premenopausal female 7.5–16.5, Postmenopausal female 10.7–24.0

13.8 ± 4.4

FRAX: major fracture (%)

20.5 ± 16.7

FRAX: hip fracture (%)

8.8 ± 11.4